Moderna 2019 Shareholder Letter

(To join our email list, click here.)
Breaking News

They knew from day one. Gates, Fauci, and even Trump all tied into this together. Direct notes from Moderna Shareholder Letter released last quarter of 2019.

Moderna 2019 Shareholder Letter  
URL: https:/  
Website Title: Moderna, Inc.

We believe mRNA vaccines have the potential to provide some critical advantages for preventing the spread of debilitating and deadly infections. A November 2019 Nature Reviews Immunology review of novel vaccine technologies from John R. Mascola and Anthony S. Fauci of the National Institutes of Health (NIH) noted the potential of mRNA as a rapid and flexible vaccine platform, stating “The combination of preclinical and clinical data bodes well for the potential of mRNA vaccines to serve as a rapid and flexible platform that will be useful in responding to both seasonal and pandemic influenza, and by extension to any newly emerging infectious agent.”

We have, over the years, established a wide range of strategic alliances with leading biopharmaceutical companies, as well as government-sponsored and private organizations focused on global health initiatives. Strategic collaborators contribute their therapeutic expertise, help to validate Moderna’s mRNA platform and have provided a quarter of our total capital to date. As of September 30, 2019, Moderna had up to $187 million in additional funding available from grants (including amounts not yet committed) [1].

[1] Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA) and The Bill and Melinda Gates Foundation (BMGF). Additional funding is subject to agreement on scope of additional projects.Attachments
© 2007-2021 Walk In Verse All rights reserved

Share This

Share on facebook
Share on twitter
Share on telegram
Share on tumblr

Get News & Updates

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top